Caseware UK (AP4) 2025.0.111 2025.0.111 2025-12-312025-12-31false2025-01-01No description of principal activity78truetruefalseThe members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006. 06161365 2025-01-01 2025-12-31 06161365 2024-01-01 2024-12-31 06161365 2025-12-31 06161365 2024-12-31 06161365 c:Director2 2025-01-01 2025-12-31 06161365 d:Buildings d:LongLeaseholdAssets 2025-01-01 2025-12-31 06161365 d:Buildings d:LongLeaseholdAssets 2025-12-31 06161365 d:Buildings d:LongLeaseholdAssets 2024-12-31 06161365 d:OfficeEquipment 2025-01-01 2025-12-31 06161365 d:OfficeEquipment 2025-12-31 06161365 d:OfficeEquipment 2024-12-31 06161365 d:OfficeEquipment d:OwnedOrFreeholdAssets 2025-01-01 2025-12-31 06161365 d:OwnedOrFreeholdAssets 2025-01-01 2025-12-31 06161365 d:CurrentFinancialInstruments 2025-12-31 06161365 d:CurrentFinancialInstruments 2024-12-31 06161365 d:CurrentFinancialInstruments d:WithinOneYear 2025-12-31 06161365 d:CurrentFinancialInstruments d:WithinOneYear 2024-12-31 06161365 d:ShareCapital 2025-12-31 06161365 d:ShareCapital 2024-12-31 06161365 d:RetainedEarningsAccumulatedLosses 2025-12-31 06161365 d:RetainedEarningsAccumulatedLosses 2024-12-31 06161365 c:FRS102 2025-01-01 2025-12-31 06161365 c:AuditExempt-NoAccountantsReport 2025-01-01 2025-12-31 06161365 c:FullAccounts 2025-01-01 2025-12-31 06161365 c:PrivateLimitedCompanyLtd 2025-01-01 2025-12-31 06161365 2 2025-01-01 2025-12-31 06161365 6 2025-01-01 2025-12-31 06161365 e:PoundSterling 2025-01-01 2025-12-31 iso4217:GBP xbrli:pure
Registered number: 06161365







UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED
31 DECEMBER 2025


RHODES PHARMA LIMITED







































 


RHODES PHARMA LIMITED
REGISTERED NUMBER:06161365



STATEMENT OF FINANCIAL POSITION
AS AT 31 DECEMBER 2025

2025
2024
Note
£
£

Fixed assets
  

Tangible assets
 4 
-
43,889

Investments
 5 
2,585,326
532,775

  
2,585,326
576,664

Current assets
  

Stocks
  
-
867,502

Debtors: amounts falling due within one year
 6 
54,577
648,510

Cash at bank and in hand
  
420,634
1,853,265

  
475,211
3,369,277

Creditors: amounts falling due within one year
 7 
(526,842)
(645,663)

Net current (liabilities)/assets
  
 
 
(51,631)
 
 
2,723,614

Total assets less current liabilities
  
2,533,695
3,300,278

  

Net assets
  
2,533,695
3,300,278


Capital and reserves
  

Called up share capital 
  
400
400

Profit and loss account
  
2,533,295
3,299,878

  
2,533,695
3,300,278


The directors consider that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the statement of income and retained earnings in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf on 2 June 2026.




Mr I Moosa
Director
Page 1

 


RHODES PHARMA LIMITED
REGISTERED NUMBER:06161365


    
STATEMENT OF FINANCIAL POSITION (CONTINUED)
AS AT 31 DECEMBER 2025


The notes on pages 3 to 8 form part of these financial statements.

Page 2

 


RHODES PHARMA LIMITED
 


 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

1.


General information

The company is a private company limited by share capital, incorporated in United Kingdom.

The address of its registered office is:

Newlands House 
60 Chainhouse Lane
Whitestake
Preston
Lancashire
PR4 4LG

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and the Republic of Ireland and the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The following principal accounting policies have been applied:

 
2.2

Foreign currency translation

Functional and presentation currency

The Company's functional and presentational currency is GBP.

Transactions and balances

Foreign currency transactions are translated into the functional currency using the spot exchange rates at the dates of the transactions.

At each period end foreign currency monetary items are translated using the closing rate. Non-monetary items measured at historical cost are translated using the exchange rate at the date of the transaction and non-monetary items measured at fair value are measured using the exchange rate when fair value was determined.

Foreign exchange gains and losses resulting from the settlement of transactions and from the translation at period-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognised in profit or loss except when deferred in other comprehensive income as qualifying cash flow hedges.

Foreign exchange gains and losses that relate to borrowings and cash and cash equivalents are presented in the Statement of income and retained earnings within 'finance income or costs'. All other foreign exchange gains and losses are presented in profit or loss within 'other operating income'.

Page 3

 


RHODES PHARMA LIMITED
 


 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

2.Accounting policies (continued)

 
2.3

Revenue

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured. Revenue is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. The following criteria must also be met before revenue is recognised:

Sale of goods

Revenue from the sale of goods is recognised when all of the following conditions are satisfied:
the Company has transferred the significant risks and rewards of ownership to the buyer;
the Company retains neither continuing managerial involvement to the degree usually associated with ownership nor effective control over the goods sold;
the amount of revenue can be measured reliably;
it is probable that the Company will receive the consideration due under the transaction; and
the costs incurred or to be incurred in respect of the transaction can be measured reliably.

Rendering of services

Revenue from a contract to provide services is recognised in the period in which the services are provided in accordance with the stage of completion of the contract when all of the following conditions are satisfied:
the amount of revenue can be measured reliably;
it is probable that the Company will receive the consideration due under the contract;
the stage of completion of the contract at the end of the reporting period can be measured reliably; and
the costs incurred and the costs to complete the contract can be measured reliably.

 
2.4

Operating leases: the Company as lessee

Rentals paid under operating leases are charged to profit or loss on a straight-line basis over the lease term.

Benefits received and receivable as an incentive to sign an operating lease are recognised on a straight-line basis over the lease term, unless another systematic basis is representative of the time pattern of the lessee's benefit from the use of the leased asset.

 
2.5

Research and development

In the research phase of an internal project it is not possible to demonstrate that the project will generate future economic benefits and hence all expenditure on research shall be recognised as an expense when it is incurred. Intangible assets are recognised from the development phase of a project if and only if certain specific criteria are met in order to demonstrate the asset will generate probable future economic benefits and that its cost can be reliably measured. The capitalised development costs are subsequently amortised on a straight-line basis over their useful economic lives, which range from 3 to 6 years.

If it is not possible to distinguish between the research phase and the development phase of an internal project, the expenditure is treated as if it were all incurred in the research phase only.

 
2.6

Interest income

Interest income is recognised in profit or loss using the effective interest method.

Page 4

 


RHODES PHARMA LIMITED
 


 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

2.Accounting policies (continued)

 
2.7

Pensions

Defined contribution pension plan

The Company operates a defined contribution plan for its employees. A defined contribution plan is a pension plan under which the Company pays fixed contributions into a separate entity. Once the contributions have been paid the Company has no further payment obligations.

The contributions are recognised as an expense in profit or loss when they fall due. Amounts not paid are shown in accruals as a liability in the Statement of financial position. The assets of the plan are held separately from the Company in independently administered funds.

 
2.8

Taxation

Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the Company operates and generates income.


 
2.9

Development costs

Enter user text here... 

 
2.10

Tangible fixed assets

Tangible fixed assets under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, using the straight-line method.

Depreciation is provided on the following basis:

Long-term leasehold property
-
14% - 39%
Office equipment
-
25% - 33%

The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date.

Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in profit or loss.

Page 5

 


RHODES PHARMA LIMITED
 


 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

2.Accounting policies (continued)

 
2.11

Valuation of investments

Investments in subsidiaries are measured at cost less accumulated impairment.

Investments in unlisted Company shares, whose market value can be reliably determined, are remeasured to market value at each reporting date. Gains and losses on remeasurement are recognised in the Statement of income and retained earnings for the period. Where market value cannot be reliably determined, such investments are stated at historic cost less impairment.

Investments in listed company shares are remeasured to market value at each reporting date. Gains and losses on remeasurement are recognised in profit or loss for the period.

 
2.12

Stocks

Stocks are stated at the lower of cost and net realisable value, being the estimated selling price less costs to complete and sell. Cost is based on the cost of purchase on a weighted average basis. Work in progress and finished goods include labour and attributable overheads.

At each reporting date, stocks are assessed for impairment. If stock is impaired, the carrying amount is reduced to its selling price less costs to complete and sell. The impairment loss is recognised immediately in profit or loss.

 
2.13

Debtors

Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

 
2.14

Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

 
2.15

Creditors

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

 
2.16

Dividends

Equity dividends are recognised when they become legally payable. Interim equity dividends are recognised when paid. Final equity dividends are recognised when approved by the shareholders at an annual general meeting.


3.


Employees

The average monthly number of employees, including directors, during the year was 7 (2024 - 8).

Page 6

 


RHODES PHARMA LIMITED
 


 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

4.


Tangible fixed assets


Long-term leasehold property
Office equipment
Total

£
£
£





At 1 January 2025
60,012
688
60,700


Additions
12,000
2,744
14,744


Transfers intra group
(29,944)
(3,432)
(33,376)


Disposals
(42,068)
-
(42,068)



At 31 December 2025

-
-
-





At 1 January 2025
16,768
43
16,811


Charge for the year on owned assets
11,127
402
11,529


Transfers intra group
(8,897)
(445)
(9,342)


Disposals
(18,998)
-
(18,998)



At 31 December 2025

-
-
-



Net book value



At 31 December 2025
-
-
-



At 31 December 2024
43,244
645
43,889


5.


Fixed asset investments





Investments in subsidiary companies
Listed investments
Total

£
£
£



Cost or valuation


At 1 January 2025
-
532,775
532,775


Additions
2,038,747
13,804
2,052,551



At 31 December 2025
2,038,747
546,579
2,585,326





6.


Debtors

2025
2024
£
£


Trade debtors
53,950
530,260

Other debtors
-
105,548
Page 7

 


RHODES PHARMA LIMITED
 


 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

6.Debtors (continued)


Prepayments and accrued income
627
12,702

54,577
648,510



7.


Creditors: Amounts falling due within one year

2025
2024
£
£

Trade creditors
7,624
329,463

Amounts owed to group undertakings
149,530
-

Other taxation and social security
294,778
52,606

Other creditors
68,850
245,275

Accruals and deferred income
6,060
18,319

526,842
645,663


Within other creditors are amounts owed to directors' of £68,577 (2024 £239,186).

 
Page 8